Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2857-2863

  Seminerio, Jennifer L ^a   Koutroubakis, Ioannis E ^a   Ramos Rivers, Claudia ^a   Hashash, Jana G ^a   Dudekula, Anwar ^a   Regueiro, Miguel ^a   Baidoo, Leonard ^a   Barrie, Arthur ^a   Swoger, Jason ^a   Schwartz, Marc ^a   Weyant, Katherine ^a   Dunn, Michael A ^a   Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

body mass index; Crohn's disease; obesity; quality of life; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOCHEMICAL MARKER; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; MERCAPTOPURINE; NARCOTIC AGENT; PREDNISONE; PURINE DERIVATIVE; WARFARIN;

ADULT; AGED; ARTICLE; BODY MASS; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REGISTER; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; COMPLICATION; DISEASE MANAGEMENT; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PSYCHOLOGY; RISK FACTOR; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MANAGEMENT; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84948158339     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000560     Document Type: Article

References (26)

1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.
2. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370: 233-244.
3. Lu B, Hiraki L, Sparks JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis. 2014;73:1914-1922.
4. Mahé E, Beauchet A, Bodemer C, et al. Psoriasis and obesity in French children: a case-control, multicentre study. 2015;172:1593-1600.
5. Chan SS, Luben R, Olsen A, et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol. 2013;108:575-582.
6. Khalili H, Ananthakrishnan AN, Konijeti GG, et al. Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2015;21:361-368.
7. Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 2008;103:2092-2098.
8. Mendall MA, Gunasekera AV, John BJ, et al. Is obesity a risk factor for Crohn's disease? Dig Dis Sci. 2011;56:837-844.
9. John BJ, Irukulla S, Abulafi AM, et al. Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther. 2006;23: 1511-1523.
10. Blain A, Cattan S, Beaugerie L, et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr. 2002;21:51-57.
11. Causey MW, Johnson EK, Miller S, et al. The impact of obesity on outcomes following major surgery for Crohn's disease: an American College of Surgeons National Surgical Quality Improvement Program assessment. Dis Colon Rectum. 2011;54:1488-1495.
12. Stabroth-Akil D, Leifeld L, Pfützer R, et al. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30:237-242.
13. WHO. Obesity: Preventing and Managing the Global Epidemic. Report on a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. Geneva, Switzerland: WHO/NUT/NCD/98.1. Technical Report Series Number 894 World Health Organization; 2000.
14. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928.
15. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn's disease. Am J Gastroenterol. 2008;103:154-161.
16. Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:986-994.
17. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000;34:1066-1069.
18. Moran GW, Dubeau MF, Kaplan GG, et al. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis. 2013;19:2949-2956.
19. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2162-2168.
20. Zwintscher NP, Horton JD, Steele SR. Obesity has minimal impact on clinical outcomes in children with inflammatory bowel disease. J Pediatr Surg. 2014;49:265-268.
21. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
22. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.
23. Hass DJ, Brensinger CM, Lewis JD, et al. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:482-488.
24. McGowan CE, Jones P, Long MD, et al. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literature. Inflamm Bowel Dis. 2012;18:49-54.
25. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19: 2118-2124.
26. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther. 2012;35:335-341.